ArticleJournal of thoracic disease2025
Association between age-adjusted visceral adiposity index and obstructive sleep apnea: a study based on NHANES 2015-2018.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obstructive sleep apnea (OSA) is a common sleep disorder that significantly impairs sleep quality and daytime functionality, with a well-established association with obesity. To enhance the precision of OSA risk assessment, this study introduces the age-adjusted visceral adiposity index (AVAI) and investigates its association with OSA. Methods: The study utilized data from the 2015-2018 National Health and Nutrition Examination Survey (NHANES). The association of AVAI with OSA was examined through a multivariate logistic regression model. Propensity score matching (PSM) was leveraged for mitigating baseline characteristic imbalances and validating the robustness of the findings. Interaction and subgroup analyses were conducted to explore potential effect modifiers. In addition, receiver operating characteristic (ROC) curve analysis was performed to evaluate the discriminative ability of AVAI for OSA. Results: Among 3,611 participants, 1,753 were diagnosed with OSA. AVAI was significantly associated with OSA [odds ratio (OR) =1.15, 95% confidence interval (CI): 1.09, 1.21]. Participants in the highest AVAI quartile (Q4) had a notably elevated likelihood of OSA in contrast to those in the lowest quartile (Q1) (OR =2.67, 95% CI: 1.96, 3.64). This relation remained significant in the PSM-adjusted sample (OR =1.14, 95% CI: 1.09, 1.20). Subgroup analyses demonstrated that the link of AVAI to OSA was particularly significant in females, non-hypertensive individuals, non-diabetic individuals, and those without cardiovascular disease. Conclusions: This cross-sectional study establishes AVAI's independent association with OSA. Clinically, AVAI may help identify current high-risk profiles to guide targeted management, though predictive applications require future validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.